http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018524990-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-30 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6813 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6844 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6876 |
| filingDate | 2016-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2018524990-A |
| titleOfInvention | Genetic signature for immunotherapy in cancer |
| abstract | Cancer immune response subtypes are associated with DNA damage, thereby enabling stratification of subjects into specific therapies, including immunotherapy, which are combined with DNA damage therapies be able to. A method for predicting responsiveness to antagonists of inhibitory immune checkpoints and / or agonists of stimulatory immune checkpoints comprises at least one gene selected from Table 2B, 2A, or 1 in a sample derived from a subject. Determining the expression level of. The determined expression levels are used to predict responsiveness to antagonists of inhibitory immune checkpoints and / or agonists of stimulatory immune checkpoints. [Selection figure] None |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7315181-B2 |
| priorityDate | 2015-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 348.